lncRNA MNX1‑AS1 promotes prostate cancer progression through regulating miR‑2113/MDM2 axis

Liang,Dong; Tian,Chuanjie; Zhang,Xiaowen

doi:10.3892/mmr.2022.12747

lncRNA MNX1‑AS1 promotes prostate cancer progression through regulating miR‑2113/MDM2 axis

Authors:
- Dong Liang
- Chuanjie Tian
- Xiaowen Zhang
View Affiliations

Affiliations: Department of Urology Surgery, Binhai County Hospital of TCM, Yancheng, Jiangsu 224500, P.R. China, Department of Urology Surgery, Heqiao Hospital, Heqiao, Yixing, Jiangsu 214200, P.R. China, Department of Urology Surgery, Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China
Published online on: May 25, 2022 https://doi.org/10.3892/mmr.2022.12747
Article Number: 231
Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A growing number of dysregulated long non‑coding (lnc)RNAs have been verified to serve an essential role in human prostate cancer. However, the underlying mechanisms of lncRNA MNX1 Antisense RNA 1 (MNX1‑AS1) in prostate cancer has not been explored. Therefore, the present study aimed to explore the function of MNX1‑AS1 in prostate cancer tumorigenesis and investigate the in‑depth mechanism. The expression of MNX1‑AS1, microRNA (miR)‑2113 and murine double min 2 (MDM2) in prostate cancer tissues and corresponding normal tissues were assessed by reverse transcription‑quantitative PCR. The protein expression levels of MDM2 were detected by western blotting. LNCaP and PC‑3 cells were transfected with short hairpin (sh)‑MNX1‑AS1, miR‑2113 mimics, miR‑2113 inhibitor and pCDH‑MDM2 vector using Lipofectamine^® 3000. Cell proliferation, migration and invasion abilities were assessed by CCK‑8 assay, colony formation and Transwell assay, respectively. Dual luciferase reporter assay was carried out to confirm the putative targets of MNX1‑AS1 and miR‑2113. Tumor formation experiment in nude mice was applied to evaluate the tumor growth effect of MNX1‑AS1 in vivo. The expression of MNX1‑AS1 was significantly upregulated in the prostate cancer tissues and cell lines. MNX1‑AS1 knockdown suppressed the abilities of cell viability and migration and invasion in vitro and inhibited tumor growth in vivo. Additionally, luciferase reporter assay revealed that MNX1‑AS1 could target miR‑2113 and negatively interacted with miR‑2113 in prostate cancer cells. miR‑2113 directly targeted to MDM2 and negatively modulated the expression of MDM2. Rescue assays suggested that the viability, migration and invasion of impaired cells triggered by transfection with sh‑MNX1‑AS1 alone could be recovered by co‑transfection with sh‑MNX1‑AS1 + miR‑2113 inhibitor or sh‑MNX1‑AS1 + pCDH‑ MDM2 vector. The present study demonstrated that MNX1‑AS1 promoted prostate cancer progression through regulating miR‑2113/ MDM2 axis.

View Figures

View References

1	Mitobe Y, Takayama KI, Horie-Inoue K and Inoue S: Prostate cancer-associated lncRNAs. Cancer Lett. 418:159–166. 2018. View Article : Google Scholar
2	Misawa A, Takayama KI and Inoue S: Long non-coding RNAs and prostate cancer. Cancer Sci. 108:2107–2114. 2017. View Article : Google Scholar
3	Chang AJ, Autio KA, Roach M III and Scher HI: High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 11:308–323. 2014. View Article : Google Scholar
4	Chi Y, Wang D, Wang J, Yu W and Yang J: Long non-coding RNA in the pathogenesis of cancers. Cells. 8:10152019. View Article : Google Scholar
5	Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell. 136:629–641. 2009. View Article : Google Scholar
6	Zhang Y, Pitchiaya S, Cieslik M, Niknafs YS, Tien JCY, Hosono Y, Iyer MK, Yazdani S, Subramaniam S, Shukla SK, et al: Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nat Genet. 50:814–824. 2018. View Article : Google Scholar
7	Zhang A, Zhao JC, Kim J, Fong KW, Yang YA, Chakravarti D, Mo YY and Yu J: LncRNA HOTAIR enhances the androgen-receptor-mediated transcriptional program and drives castration-resistant prostate cancer. Cell Rep. 13:209–221. 2015. View Article : Google Scholar : PubMed/NCBI
8	Gu P, Chen X, Xie R, Han J, Xie W, Wang B, Dong W, Chen C, Yang M, Jiang J, et al: lncRNA HOXD-AS1 regulates proliferation and chemo-resistance of castration-resistant prostate cancer via recruiting WDR5. Mol Ther. 25:1959–1973. 2017. View Article : Google Scholar : PubMed/NCBI
9	Sun M, Geng D, Li S, Chen Z and Zhao W: LncRNA PART1 modulates toll-like receptor pathways to influence cell proliferation and apoptosis in prostate cancer cells. Biol Chem. 399:387–395. 2018. View Article : Google Scholar : PubMed/NCBI
10	Shang Z, Yu J, Sun L, Tian J, Zhu S, Zhang B, Dong Q, Jiang N, Flores-Morales A, Chang C and Niu Y: LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex. Nucleic Acids Res. 47:4211–4225. 2019. View Article : Google Scholar : PubMed/NCBI
11	Wu M, Huang Y, Chen T, Wang W, Yang S, Ye Z and Xi X: LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis. J Cell Mol Med. 23:29–38. 2019. View Article : Google Scholar : PubMed/NCBI
12	Hua JT, Chen S and He HH: Landscape of noncoding RNA in prostate cancer. Trends Genet. 35:840–851. 2019. View Article : Google Scholar
13	Shuai Y, Ma Z, Liu W, Yu T, Yan C, Jiang H, Tian S, Xu T and Shu Y: TEAD4 modulated LncRNA MNX1-AS1 contributes to gastric cancer progression partly through suppressing BTG2 and activating BCL2. Mol Cancer. 19:62020. View Article : Google Scholar : PubMed/NCBI
14	Chu J, Li H, Xing Y, Jia J, Sheng J, Yang L, Sun K, Qu Y, Zhang Y, Yin H, et al: LncRNA MNX1-AS1 promotes progression of esophageal squamous cell carcinoma by regulating miR-34a/SIRT1 axis. Biomed Pharmacother. 116:1090292019. View Article : Google Scholar : PubMed/NCBI
15	Gao Y, Xu Y, Wang J, Yang X, Wen L and Feng J: lncRNA MNX1-AS1 promotes glioblastoma progression through inhibition of miR-4443. Oncol Res. 27:341–347. 2019. View Article : Google Scholar : PubMed/NCBI
16	Liu X, Yang Q, Yan J, Zhang X and Zheng M: LncRNA MNX1-AS1 promotes the progression of cervical cancer through activating MAPK pathway. J Cell Biochem. 120:4268–4277. 2019. View Article : Google Scholar : PubMed/NCBI
17	Liu G, Guo X, Zhang Y, Liu Y, Li D, Tang G and Cui S: Expression and significance of LncRNA MNX1-AS1 in non-small cell lung cancer. Onco Targets Ther. 12:3129–3138. 2019. View Article : Google Scholar : PubMed/NCBI
18	Li Z, Wang F and Zhang S: Knockdown of lncRNA MNX1-AS1 suppresses cell proliferation, migration, and invasion in prostate cancer. FEBS Open Bio. 9:851–858. 2019. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Li JH, Liu S, Zhou H, Qu LH and Yang JH: starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 42:D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
21	Zheng A, Song X, Zhang L, Zhao L, Mao X, Wei M and Jin F: Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via wnt/β-catenin pathway. J Exp Clin Cancer Res. 38:3052019. View Article : Google Scholar : PubMed/NCBI
22	Pritt SL and Smith TM: Institutional animal care and use committee postapproval monitoring programs: A proposed comprehensive classification scheme. J Am Assoc Lab Anim Sci. 59:127–131. 2020. View Article : Google Scholar
23	Ji D, Wang Y, Sun B, Yang J and Luo X: Long non-coding RNA MNX1-AS1 promotes hepatocellular carcinoma proliferation and invasion through targeting miR-218-5p/COMMD8 axis. Biochem Biophys Res Commun. 513:669–674. 2019. View Article : Google Scholar : PubMed/NCBI
24	Li J, Li Q, Li D, Shen Z, Zhang K, Bi Z and Li Y: Long non-coding RNA MNX1-AS1 promotes progression of triple negative breast cancer by enhancing phosphorylation of Stat3. Front Oncol. 10:11082020. View Article : Google Scholar
25	Liu H, Han L, Liu Z and Gao N: Long noncoding RNA MNX1-AS1 contributes to lung cancer progression through the miR-527/BRF2 pathway. J Cell Physiol. 234:13843–13850. 2019. View Article : Google Scholar
26	Lv Y, Li H, Li F, Liu P and Zhao X: Long noncoding RNA MNX1-AS1 knockdown inhibits cell proliferation and migration in ovarian cancer. Cancer Biother Radiopharm. 32:91–99. 2017. View Article : Google Scholar : PubMed/NCBI
27	Wang J, Xing H, Nikzad AA, Liu B, Zhang Y, Li S, Zhang E and Jia Z: Long noncoding RNA MNX1 antisense RNA 1 exerts oncogenic functions in bladder cancer by regulating miR-218-5p/RAB1A axis. J Pharmacol Exp Ther. 372:237–247. 2020. View Article : Google Scholar : PubMed/NCBI
28	Zhang W, Huang L, Lu X, Wang K, Ning X and Liu Z: Upregulated expression of MNX1-AS1 long noncoding RNA predicts poor prognosis in gastric cancer. Bosn J Basic Med Sci. 19:164–171. 2019.
29	Cheng Y, Pan Y, Pan Y and Wang O: MNX1-AS1 is a functional oncogene that induces EMT and activates the AKT/mTOR pathway and MNX1 in breast cancer. Cancer Manag Res. 11:803–812. 2019. View Article : Google Scholar : PubMed/NCBI
30	Xue LP, Fu XL, Hu M, Zhang LW, Li YD, Peng YL and Ding P: Rg1 inhibits high glucose-induced mesenchymal activation and fibrosis via regulating miR-2113/RP11-982M15.8/Zeb1 pathway. Biochem Biophys Res Commun. 501:827–832. 2018. View Article : Google Scholar : PubMed/NCBI
31	Zhang L, Chen Y, Bao C, Zhang X and Li H: Eukaryotic initiation factor 4AIII facilitates hepatocellular carcinoma cell proliferation, migration, and epithelial-mesenchymal transition process via antagonistically binding to WD repeat domain 66 with miRNA-2113. J Cell Physiol. 235:8199–8209. 2020. View Article : Google Scholar
32	Wade M, Li YC and Wahl GM: MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 13:83–96. 2013. View Article : Google Scholar : PubMed/NCBI
33	Ren ZJ, Nong XY, Lv YR, Sun HH, An PP, Wang F, Li X, Liu M and Tang H: Mir-509-5p joins the Mdm2/p53 feedback loop and regulates cancer cell growth. Cell Death Dis. 5:e13872014. View Article : Google Scholar : PubMed/NCBI
34	Fortunato O, Boeri M, Moro M, Verri C, Mensah M, Conte D, Caleca L, Roz L, Pastorino L and Sozzi G: Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction. Cell Death Dis. 5:e15642014. View Article : Google Scholar : PubMed/NCBI
35	Chen Y, Wang DD, Wu YP, Su D, Zhou TY, Gai RH, Fu YY, Zheng L, He QJ, Zhu H and Yang B: MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells. Br J Cancer. 117:1192–1201. 2017. View Article : Google Scholar : PubMed/NCBI
36	Wu D, Niu X, Tao J, Li P, Lu Q, Xu A, Chen W and Wang Z: MicroRNA-379-5p plays a tumor-suppressive role in human bladder cancer growth and metastasis by directly targeting MDM2. Oncol Rep. 37:3502–3508. 2017. View Article : Google Scholar : PubMed/NCBI
37	Cai Y, Hao Y, Ren H, Dang Z, Xu H, Xue X and Gao Y: miR-1305 inhibits the progression of non-small cell lung cancer by regulating MDM2. Cancer Manag Res. 11:9529–9540. 2019. View Article : Google Scholar : PubMed/NCBI
38	Shen J, Niu W, Zhou M and Zhang H, Ma J, Wang L and Zhang H: MicroRNA-410 suppresses migration and invasion by targeting MDM2 in gastric cancer. PLoS One. 9:e1045102014. View Article : Google Scholar : PubMed/NCBI
39	Tian XM, Luo YZ, He P, Li J, Ma ZW and An Y: Inhibition of invasion and migration of prostate cancer cells by miRNA-509-5p via targeting MDM2. Genet Mol Res. 16:232017. View Article : Google Scholar
40	Moradimotlagh A, Arefian E, Valojerdi RR, Ghaemi S, Adegani FJ and Soleimani M: MicroRNA-129 inhibits glioma cell growth by targeting CDK4, CDK6, and MDM2. Mol Ther Nucleic Acids. 19:759–764. 2020. View Article : Google Scholar : PubMed/NCBI